BioTech IP Review

Patent Number: US 12,291,562 B2
Issued: 2025 (date not specifically listed in public sources but indexed as 2025)
Title: Reagents and Assays Using Modified Integrin Domains
Inventor: Vineet Gupta
Assignee: (listed under academic/industry shared ownership, not explicitly Gossamer Bio in public index)
Field: Integrin targeting reagents and assays

What This Patent Covers

This patent relates to the design and use of modified integrin domain reagents and associated assay methods. Specifically, it protects:

• Engineered integrin domain proteins or fragments that bind selectively to integrin receptors (such as CD11b).
• Reagents and assay formats for detecting, quantifying, or modulating integrin interactions in biological samples.
• Applications include screening and characterizing integrin function, which can support drug discovery efforts targeting integrin pathways.
• The underlying innovations enable precise biochemical analyses of integrin behavior and interactions, foundational to developing targeted therapies that modulate immune cell activity.

Why This Is Important

• Relevance to Gossamer Bio’s pipeline: Gossamer’s clinical‑stage small molecule GB‑1275 — a CD11b (integrin alpha M) activator — originated from research tied to integrin modulation strategies. Although the direct patent assignments may sit under academic partners, technology like this underpins assay and screening capabilities that support small molecule development.
• Enabling discovery tools: Assays and reagents for integrins are essential for validating drug candidates like GB‑1275 and understanding mechanistic effects on innate immune cells, which is central to potential indications in cancer and immune regulation.
• Indirect value: Even if the patent isn’t held directly by Gossamer, patents from key collaborators (e.g., scientists/institutions feeding into Gossamer’s programs) can significantly enhance a company’s competitive position by restricting use of core tools by competitors.

---

• Gossamer Bio’s clinical innovation focus centers on seralutinib for pulmonary hypertension and earlier‑stage programs like GB‑1275 (CD11b integrator activator) — but public records don’t currently show a newly granted company‑assigned patent.
• The company’s existing seralutinib patent estate comes from licensed patents covering compound, formulation, and method of use claims from collaborators like Pulmokine and Gilead Sci., with expiry dates beyond 2034.